Biovail building cash reserves, reduces debt

Canada's Biovail has slashed its revolving line of credit by 37.5 percent, part of the company's strategy to wipe out its dependence on debt. Biovail spent $280 million to clear its line of credit last year and more than $66 million to reduce long-term debt. Biovail also has $230 million in cash on hand compared to $100 million last February.

- read this article from The Globe and Mail for more on Biovail

PLUS: The FDA has approved Biovail's formulation of zolpidem tartrate for insomnia. Story

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.